Table 1.
Patient Demographics and Baseline Characteristics
| Characteristics | Patients (N = 62) |
|---|---|
| Median age, years (range)a | 57 (23–75) |
| Age, years, n (%) | |
| <65 | 50 (80.6) |
| ≥65 | 12 (19.4) |
| Sex, n (%) | |
| Female | 6 (9.7) |
| Male | 56 (90.3) |
| ECOG PS, n (%) | |
| 0 | 60 (96.8) |
| 1 | 2 (3.2) |
| Etiology, n (%) | |
| Hepatitis B infection | 57 (91.9) |
| Unknown | 5 (8.1) |
| HBV-DNA copy, n (%) | |
| < 1000 copy/mL | 28 (45.2) |
| ≥ 1000 copy/mL | 34 (54.8) |
| Pre-treatment AFP, n (%) | |
| < 400 ng/mL | 30 (48.4) |
| ≥ 400 ng/mL | 32 (51.6) |
| Pre-treatment PIVKA-II, mAU/mL, n (%) | |
| < 400 mAU/mL | 17 (27.4) |
| ≥ 400 mAU/mL | 45 (72.6) |
| Tumor number, n (%) | |
| Solitary | 25 (40.3) |
| Multiple | 37 (59.7) |
| Median tumor size, cm (range)a | 9.7 (2–21.7) |
| Tumor size, cm, n (%) | |
| <10 | 31 (50) |
| ≥10 | 31 (50) |
| Tumor Location, n (%) | |
| Unilobar | 31 (50) |
| Bilobar | 26 (41.9) |
| Central | 5 (8.1) |
| Portal vein invasion, n (%) | |
| Vp0 | 35 (56.5) |
| Vp2 | 4 (6.5) |
| Vp3 | 12 (19.4) |
| Vp4 | 11 (17.7) |
| Hepatic vein tumor thrombus, n (%) | |
| Vv0 | 47 (75.8) |
| Vv1 | 7 (11.3) |
| Vv2 | 3 (4.8) |
| Vv3 | 5 (8.1) |
| Macrovascular invasion, n (%) | 34 (54.8) |
| Extrahepatic metastasis, n (%) | 6 (9.7) |
| BCLC staging, n (%) | |
| A | 6 (9.7) |
| B | 21 (33.9) |
| C | 35 (56.5) |
Note: aContinuous data with a normal distribution are expressed as mean ± SD.
Abbreviations: ECOG PS, Eastern Cooperative Oncology Group performance status; AFP, α-fetoprotein; PIVKA-II, protein induced by vitamin K absence-II; BCLC, Barcelona Clinic Liver Cancer.